Maxcyte, Inc.
MXCT- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- SEC CIK
- 0001287098
No open-market purchases or sales by Maxcyte, Inc. insiders were filed in the last 90 days; 122 institutions reported holding it in 13F filings for Q2 2026, worth $78.0M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Maxcyte, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Of which not filed for Q3 2022 | Q3 2022 | Change |
|---|---|---|---|---|
| Holders | 104 | 1 | 109 | +6 |
| Shares | 68.3M | 502 | 69.9M | +1.57M (+2.3%) |
| Value | $322.7M | $2.33K | $453.8M | +$131.1M (+40.6%) |
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Maxcyte, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Blue Water Life Science Advisors, LLC | 3,225,000 | $21.0M | 8.46% |
| Premier Fund Managers Ltd | 255,395 | $1.60M | 0.12% |
| Baillie Gifford & Co | 202,800 | $1.31M | 0.00% |
| Granahan Investment Management Inc | 98,201 | $638.0K | 0.02% |
| Tamarack Advisers, LP | 82,099 | $534.0K | 0.32% |
| Mudita Advisors LLP | 61,234 | $398.0K | 0.37% |
| Algert Global LLC | 43,934 | $286.0K | 0.02% |
| Advisory Research Inc | 35,410 | $230.0K | 0.02% |
| Point72 Asset Management, L.P. | 34,900 | $227.0K | 0.00% |
| Valmark Advisers, Inc. | 34,559 | $225.0K | 0.00% |
| Price T Rowe Associates Inc | 13,493 | $88.0K | 0.00% |
| Brown Brothers Harriman & Co | 6,255 | $41.0K | 0.00% |
| Salem Investment Counselors Inc | 3,800 | $25.0K | 0.00% |
| Capital Analysts, LLC | 1,146 | $7.00K | 0.00% |
| China Universal Asset Management Co., Ltd. | 952 | $6.00K | 0.00% |
| Almanack Investment Partners, LLC. | 664 | $4.00K | 0.00% |
| Signaturefd, LLC | 362 | $2.00K | 0.00% |
| Massmutual Trust Co FSB | 48 | $0 | 0.00% |
Sold out (12)
Institutions that held Maxcyte, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| RTW Investments, LP | 772,735 | $3.65M |
| Marshall Wace, LLP | 257,068 | $1.22M |
| Ergoteles LLC | 64,500 | $305.0K |
| Two Sigma Investments, LP | 56,294 | $266.0K |
| Man Group plc | – | $189.0K |
| Squarepoint Ops LLC | 24,000 | $114.0K |
| Cantor Fitzgerald, L. P. | 25,169 | $113.0K |
| Qube Research & Technologies Ltd | 20,930 | $99.0K |
| PDT Partners, LLC | 16,080 | $76.0K |
| Quantbot Technologies LP | 5,782 | $27.0K |
| State of Wyoming | 4,071 | $19.0K |
| Total Clarity Wealth Management, Inc. | 1,518 | $7.00K |
Not filed for Q3 2022 yet (1)
Institutions that held Maxcyte, Inc. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Exane Derivatives | 502 | $2.33K |